Asthma is a heterogeneous chronic inflammatory disease of the airways that affects
approximately 300 million people worldwide. About 5–10% of all asthmatics suffer from …

Asthma is a common chronic inflammatory condition of the airways that affects about 350
million people globally. In 5%–10% of individuals, it is severe, with considerable morbidity …

Biologic Therapies for Severe Asthma Patients with severe asthma are at increased risk for a
decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may …

Asthma is a respiratory disorder with considerable heterogeneity in aetiology, triggers,
clinical characteristics and response to therapy. This diversity reflects different inflammatory …

Biological drugs have revolutionized the management of severe asthma. However, a
variable number of patients remain uncontrolled or only partially controlled even after the …

Objective Severe asthma affects 5% to 10% of the adult asthma population and is
associated with increased morbidity, mortality, and consumption of health care resources …

Evaluation and effective management of asthma, and in particular severe asthma, remains
at the core of pulmonary practice. Over the last 20–30 years, there has been increasing …

Patients with severe asthma that remain uncontrolled incur significant medical burden and
healthcare costs. Severe asthma is a heterogeneous airway disorder with complex …

Advances in pathophysiological understanding and the elucidation of a type 2 inflammatory
signature with interleukins 4, 5 and 13 at its center have led to the development of targeted …

Asthma is one of the most common noncommunicable diseases; in the majority of patients it
is well controlled with inhaled bronchodilators and inhaled corticosteroids, but the …